Misitatug blivedotin (RC88) is an antibody-drug conjugate ( ADC ) targeting mesothelin ( MSLN ). Misitatug blivedotin binds to mesothelin and exhibits dose‐dependent antitumor activity. Misitatug blivedotin can be used for the research of ovarian cancer, non-squamous non-small-cell lung carcinoma, cervical cancer [1] [2].
In Vivo, Misitatug blivedotin (0.7-3 mg/kg; i.v.; Q1W × 1 or Q1W × 3) exhibits dose‐dependent antitumor activity in female Balb/c nude mice implanted subcutaneously with 3 million OVCAR3‐MSLN‐3# or H292‐MSLN‐9C8 cells[2].
In Vitro, RC88 effectively blocks CA125 from binding to MSLN[3].
References:
[1]. Liu YT, et al. The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study. J Clin Oncol. 2024 May 29;42:5551.
[2]. Li Q, et al. Translation of the efficacy of antibody-drug conjugates from preclinical to clinical using a semimechanistic PK/PD model: A case study with RC88. Clin Transl Sci. 2023 Jul;16(7):1232-1242.
[3]. Wang l, et al. Abstract 2862: Anti MSLN ADC RC88 engages unique binding to target positive tumor cells with less interference from the soluble MSLN protein. Cancer Res.2015;85.
In Vivo, Misitatug blivedotin (0.7-3 mg/kg; i.v.; Q1W × 1 or Q1W × 3) exhibits dose‐dependent antitumor activity in female Balb/c nude mice implanted subcutaneously with 3 million OVCAR3‐MSLN‐3# or H292‐MSLN‐9C8 cells[2].
In Vitro, RC88 effectively blocks CA125 from binding to MSLN[3].
References:
[1]. Liu YT, et al. The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study. J Clin Oncol. 2024 May 29;42:5551.
[2]. Li Q, et al. Translation of the efficacy of antibody-drug conjugates from preclinical to clinical using a semimechanistic PK/PD model: A case study with RC88. Clin Transl Sci. 2023 Jul;16(7):1232-1242.
[3]. Wang l, et al. Abstract 2862: Anti MSLN ADC RC88 engages unique binding to target positive tumor cells with less interference from the soluble MSLN protein. Cancer Res.2015;85.